{
  "id": "cluster_6_doc3",
  "content": "A 9-year-old patient presented at Southwest Allergy Center with persistent nighttime wheezing despite using Flovent HFA. Treatment plan included omalizumab injections (150mg monthly) under prior auth CB-7829. The case was flagged for potential step therapy exemption due to clinical severity.",
  "metadata": {
    "format": "medical_record"
  }
}